Icon Bioscience Inc., an eye drug company planning to submit its lead drug for approval next year, raised nearly $15 million from eight investors in the first round of a Series B fundraising, according to a Securities and Exchange Commission filing Wednesday. The Sunnyvale-based company, with offices in Redwood City, will use the money to move forward with some of its clinical trials, including a second pivotal study of ICI-10090, a treatment for controlling inflammation from cataract surgery, said CEO William “Sandy” White. It plans to submit that drug for approval toward the end of 2014, White said.
Help employers find you! Check out all the jobs and post your resume.
